Dr. Michael Auerbach, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
5233 King Ave Ste 308
Baltimore, MD 21237
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York Medical College (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 546
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D0033551
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Medstar Franklin Square Medical Center Rosedale, MD
Medical groups
- American Oncology PArtners PA (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 546
- Services billed
- 129,037
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 78,082 | 74 |
| Injection, ferric derisomaltose, 10 mg | 25,900 | 175 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21,420 | 26 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 4,910 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,834 | 24 |
| Insertion of needle into vein for collection of blood sample | 1,582 | 544 |
| Injection, denosumab, 1 mg | 1,500 | 12 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,348 | 475 |
| Injection, palonosetron hcl, 25 mcg | 920 | 17 |
| Injection, iron dextran, 50 mg | 784 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Baltimore, MD | 59 |
| Acyclovir Other prescribers in Baltimore, MD | 42 |
| Anastrozole Other prescribers in Baltimore, MD | 25 |
| Lenalidomide | 23 |
| Chlorhexidine Gluconate Other prescribers in Baltimore, MD | 21 |
| Xarelto (rivaroxaban) Other prescribers in Baltimore, MD | 18 |
| Revlimid (lenalidomide) | 15 |
| Pomalyst (pomalidomide) | 13 |
| Sprycel (dasatinib) | 12 |
| Pyrukynd (mitapivat sulfate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 51 payments worth $1,167 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $186 |
|---|---|
| Pfizer Inc. | $110 |
| Janssen Biotech, Inc. | $90.26 |
| E.r. Squibb & Sons, L.l.c. | $70.03 |
| Regeneron Healthcare Solutions, Inc. | $65.83 |
| AbbVie Inc. | $63.63 |
| AstraZeneca Pharmaceuticals LP | $62.21 |
| GlaxoSmithKline, LLC. | $54.78 |
| Food and Beverage | $1,167 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.